These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35276361)

  • 21. [MALDI-ToF mass-spectrometry in analysis of genetically determined resistance of Streptococcus pneumoniae to fluoroquinolones].
    Malakhova MV; Vereshchagin VA; Il'ina EN; Govorun VM; Filimonova OIu; Grudinina SA; Sidorenko SV
    Antibiot Khimioter; 2007; 52(1-2):10-7. PubMed ID: 18461803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.
    Brueggemann AB; Coffman SL; Rhomberg P; Huynh H; Almer L; Nilius A; Flamm R; Doern GV
    Antimicrob Agents Chemother; 2002 Mar; 46(3):680-8. PubMed ID: 11850248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The first steps towards fluoroquinolone resistance in Hungarian pneumococci.
    Dobay O; Rozgonyi F; Ghidán A; Matuz M; Nagy K; Amyes SG
    J Chemother; 2006 Dec; 18(6):624-7. PubMed ID: 17267340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone].
    Parra-Ruiz J; Hernández-Quero J
    Rev Esp Quimioter; 2012 Dec; 25(4):245-51. PubMed ID: 23303254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.
    Montanari MP; Tili E; Cochetti I; Mingoia M; Manzin A; Varaldo PE
    Microb Drug Resist; 2004; 10(3):209-17. PubMed ID: 15383164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
    Bhagwat SS; McGhee P; Kosowska-Shick K; Patel MV; Appelbaum PC
    Antimicrob Agents Chemother; 2009 Feb; 53(2):811-3. PubMed ID: 19029326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.
    Morrow BJ; Abbanat D; Baum EZ; Crespo-Carbone SM; Davies TA; He W; Shang W; Queenan AM; Lynch AS
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5512-21. PubMed ID: 21911562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
    Iraurgui P; Torres MJ; Aznar J
    Enferm Infecc Microbiol Clin; 2012 Apr; 30(4):180-3. PubMed ID: 22365183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
    J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.
    Fukuda H; Kishii R; Takei M; Hosaka M
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1649-53. PubMed ID: 11353607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
    Pestova E; Beyer R; Cianciotto NP; Noskin GA; Peterson LR
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2000-4. PubMed ID: 10428926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile.
    Reck F; Alm RA; Brassil P; Newman JV; Ciaccio P; McNulty J; Barthlow H; Goteti K; Breen J; Comita-Prevoir J; Cronin M; Ehmann DE; Geng B; Godfrey AA; Fisher SL
    J Med Chem; 2012 Aug; 55(15):6916-33. PubMed ID: 22779424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.
    Valenzuela MV; Domenech M; Mateos-Martínez P; González-Camacho F; de la Campa AG; García MT
    PLoS One; 2020; 15(11):e0241780. PubMed ID: 33141832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 4-Substituted 4-(1H-1,2,3-triazol-1-yl)piperidine: novel C7 moieties of fluoroquinolones as antibacterial agents.
    Huang X; Zhang A; Chen D; Jia Z; Li X
    Bioorg Med Chem Lett; 2010 May; 20(9):2859-63. PubMed ID: 20347299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Korzheva N; Davies TA; Goldschmidt R
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
    Lapointe G; Skepper CK; Holder LM; Armstrong D; Bellamacina C; Blais J; Bussiere D; Bian J; Cepura C; Chan H; Dean CR; De Pascale G; Dhumale B; Fisher LM; Fulsunder M; Kantariya B; Kim J; King S; Kossy L; Kulkarni U; Lakshman J; Leeds JA; Ling X; Lvov A; Ma S; Malekar S; McKenney D; Mergo W; Metzger L; Mhaske K; Moser HE; Mostafavi M; Namballa S; Noeske J; Osborne C; Patel A; Patel D; Patel T; Piechon P; Polyakov V; Prajapati K; Prosen KR; Reck F; Richie DL; Sanderson MR; Satasia S; Savani B; Selvarajah J; Sethuraman V; Shu W; Tashiro K; Thompson KV; Vaarla K; Vala L; Veselkov DA; Vo J; Vora B; Wagner T; Wedel L; Williams SL; Yendluri S; Yue Q; Yifru A; Zhang Y; Rivkin A
    J Med Chem; 2021 May; 64(9):6329-6357. PubMed ID: 33929852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
    Morrow BJ; He W; Amsler KM; Foleno BD; Macielag MJ; Lynch AS; Bush K
    Antimicrob Agents Chemother; 2010 May; 54(5):1955-64. PubMed ID: 20176911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
    Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
    Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
    J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.